Search Within

Jasmeet Chadha Singh

Formats
  1. Meeting Abstract (12)
  2. Journal Article (8)
  3. Review (2)
  4. Book Section (1)
Groups
  1. Breast Medicine Service (23)
  2. Department of Medicine (23)
  3. Solid Tumor Oncology Division (23)
  4. Survivorship Research (18)
  5. Population Sciences Research Program (15)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (13)

More Groups

People
  1. Chau Dang (15)
  2. Larry Norton (13)
  3. Clifford Hudis (10)
  4. Diana Lake (9)
  5. Jose Baselga (9)
  6. Lillian Smyth (9)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (2)
  5. 2020 (2)
  6. 2019 (3)

More Years

Publications
  1. Cancer Research (5)
  2. Journal of Clinical Oncology (4)
  3. The Oncologist (3)
  4. Annals of Oncology (2)
  5. Drugs & Aging (2)
  6. Expert Opinion on Drug Metabolism and Toxicology (2)

More Publications

Publishers
  1. American Association for Cancer Research (5)
  2. Oxford University Press (5)
  3. American Society of Clinical Oncology (4)
  4. Adis International Ltd (2)
  5. Informa Healthcare (2)
  6. Springer (2)

More Publishers

Results (23)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Predicting drug–drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning
    Review

    Kulkarni, A.; Singh, J.
    Expert Opinion on Drug Metabolism and Toxicology (2024)

    Fulltext@MSK | Save
  • Immunotherapy in older patients with breast cancer: Case study and literature review
    Meeting Abstract

    Sha, C.; Liu, M.; Lake, D.; Singh, J.; Zhi, W. I.
    Journal of the National Comprehensive Cancer Network (2024)

    Fulltext@MSK | Save
  • Older patients with early-stage triple-negative breast cancer: The Memorial Sloan Kettering Cancer Center experience
    Meeting Abstract

    Zhi, I.; Lake, D. E.; Ehrich, F.; Chen, Y.; Korc-Grodzicki, B.; Norton, L.; Robson, M. E.; Singh, J. C.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Journal Article

    Ferraro, E.; Singh, J.; Patil, S.; Razavi, P.; Modi, S.; Chandarlapaty, S.; Barrio, A. V.; Malani, R.; Mellinghoff, I. K.; Boire, A.; more...
    npj Breast Cancer (2022)

    Fulltext@MSK | Save
  • Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Wang, R.; Singh, J. C.; Wong, S. T. L.; Lake, D.; Iyengar, N. M.; D'Andrea, G.; Brockway-Marchello, J. P.; Kaba, A.; Traina, T. A.; Robson, M. E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Targeted agents for HER2-positive breast cancer: Optimal use in older patients
    Review

    Singh, J. C.; Lichtman, S. M.
    Drugs & Aging (2021)

    Fulltext@MSK | Save
  • Disease free survival rate with dose dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab (ddACTHP) in patients with HER2-positive early stage breast cancer: A single institution experience
    Meeting Abstract

    Singh, J. C.; Patil, S.; Norton, L.; Robson, M.; Dang, C.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Individualizing the approach to the older woman with triple-negative breast cancer
    Book Section

    Singh, J. C.; Lichtman, S. M.
    In Tan, A. R. (Eds.) Triple-Negative Breast Cancer: A Clinician's Guide (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A phase 2 clinical trial
    Journal Article

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Fornier, M. N.; Goldfarb, S.; Jhaveri, K.; more...
    JAMA Network Open (2019)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma
    Meeting Abstract

    Rubinstein, M. M.; Caird, I.; Zhou, Q.; Iasonos, A.; Friedman, C. F.; Cadoo, K. A.; Konner, J. A.; O'Cearbhaill, R. E.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save